

# Contents

## Basics · 1

### 1 Cerebrospinal Fluid: Spaces, Production, and Flow · 3

*H. Reiber*

### 2 Blood–Brain Barrier and Blood–CSF Barrier Function · 5

*H. Reiber*

Blood–Brain Barrier · 5

The Blood–CSF Barrier Function · 5

### 3 Dynamics of Serum and Brain Proteins in CSF and Blood · 10

*H. Reiber*

Serum Proteins in CSF · 10

Brain Proteins in Blood · 13

Brain Proteins in CSF · 12

## Analysis · 15

### 4 Principles of Analytical Methods · 17

*H. Reiber*

#### Immunochemistry · 17

Antigen–Antibody Binding · 17

Methods of Immune Complex Analysis · 18

SDS Gel Electrophoresis (One-Dimensional) · 24

Isoelectric Focusing · 24

Electrophoresis Gels · 25

Electrophoretic Methods with Immunodetection · 26

Detection of Oligoclonal IgG Bands · 28

#### Qualitative Electrophoretic Methods with or without Immunodetection · 23

Relevance and Principle of Electrophoresis · 23

Protein Electrophoresis · 24

#### Immunohistochemistry · 29

### 5 Cerebrospinal Fluid Analysis · 30

*B. Storch-Hagenlocher, H Reiber, B. Wildemann, M. Otto*

#### Cerebrospinal Puncture · 30

*B. Storch-Hagenlocher*

#### Cell count, Cytology · 35

*B. Storch-Hagenlocher*

Indications · 35

Preanalytical Requirements · 35

Procedures · 36

Findings · 38

#### Measurement of Cerebrospinal Pressure · 34

*B. Storch-Hagenlocher*

<b>Proteins</b> · 44	<b>Diagnosis of Pathogens</b> · 59
<i>H. Reiber</i>	<i>B. Wildemann, H. K. Geiss, P. Schnitzler</i>
Total Protein · 44	General Remarks · 59
CSF/Serum Albumin Quotient · 45	Microscopic Detection of Pathogens · 60
Immunoglobulins · 46	Rapid Antigen Tests · 61
Quotient Diagrams (Reibergrams) · 48	Propagation of Pathogens in Culture · 63
Statistics for Groups in Quotient Diagrams · 51	Detection of Pathogen-Specific Genome Sequences
Oligoclonal IgG · 53	Using Nucleic Acid Amplification Techniques · 65
Antibody Index · 54	Antibody Detection · 68
Relative Sensitivities of Immunodetection Methods · 55	
<b>Lactate and Glucose</b> · 56	<b>Markers of Dementia and Neuronal Destruction</b> · 69
<i>H. Reiber</i>	<i>M. Otto</i>
Lactate · 56	
Glucose · 58	

## 6 Serum Analysis · 73

*M. Zorn, M. Uhr*

<b>General Serum Analysis</b> · 73	Atherosclerosis Markers · 78
<i>M. Zorn</i>	Creatine Kinase (CK) · 80
Inflammation Markers · 73	Neuron-Specific Enolase (NSE) and S-100 Protein · 80
Angiotensin-Converting Enzyme (ACE) · 75	
Ceruloplasmin (Cp) · 76	<b>Special Serum Analysis</b> · 81
Folic Acid and Vitamin B <sub>12</sub> (Cobalamins) · 76	<i>M. Uhr</i>
Diabetes Markers · 77	Determination of Drug Levels · 81
Alcohol Markers · 77	Intoxication · 83
Endocrine Markers · 78	Determination of Vitamins · 83

## 7 Autoantibodies and Antineuronal Antibodies · 86

*B. Wildemann, U. Wurster*

<b>Autoantibodies</b> · 86	<b>Antineuronal Antibodies</b> · 91
<i>B. Wildemann</i>	<i>U. Wurster</i>
<b>8 Neurogenetics</b> · 99	
<i>T. Gasser</i>	
<b>Basics</b> · 99	<b>Polygenic or Multifactorial Hereditary Neurological Disorders</b> · 104
<b>Monogenic Hereditary Neurological Disorders</b> · 103	

## 9 Biopsy · 108

*A. Rosenbohm, A. Sperfeld, H. Tumani*

<b>Brain Biopsy</b> · 108	<b>Muscle Biopsy</b> · 109
	Basics · 109
<b>Nerve Biopsy</b> · 108	Typical Muscle Biopsy Findings · 112

**Clinical Pictures · 115****10 Inflammatory and Autoimmune Diseases · 117***B. Storch-Hagenlocher, P. Oschmann, B. Wildemann***Infections · 117**

Bacterial Infections · 117

*B. Storch-Hagenlocher*

Abscesses · 121

*B. Storch-Hagenlocher*

Ventriculitis · 122

*B. Storch-Hagenlocher*

Viral Infections of the Nervous System · 123

*P. Oschmann*

Infection of the Nervous System

by Fungi and Other Opportunistic Pathogens · 128

*P. Oschmann*

Neuroborreliosis · 130

*P. Oschmann*

Neurosypilis · 133

*P. Oschmann*

Chronic Infections of the Nervous System · 135

*P. Oschmann***Non-Pathogen-Related Inflammatory Disorders:****Autoimmune Diseases · 138***B. Wildemann*

Multiple Sclerosis · 138

Acute Demyelinating Encephalomyelitis and MS Variants · 141

Neurosarcoidosis · 141

Stiff Person Syndrome and Other Neurological Diseases

Associated with GAD Antibodies · 143

Myasthenia Gravis and Other Disorders of Neuromuscular Transmission · 144

Lambert-Eaton Myasthenic Syndrome · 145

Neuromyotonia · 145

Polymyositis, Dermatomyositis, and Inclusion Body

Myositis · 146

Guillain-Barré Syndrome and Other Immune-Mediated

Neuropathies · 147

Systemic Vasculitis and Connective Tissue Diseases · 154

Paraneoplastic Neurological Syndromes · 159

**11 Dementia and Other Psychiatric Disorders · 166***M. Otto, M. Uhr***Alzheimer's Disease · 166***M. Otto***Multiple System Atrophy · 173***M. Otto***Lewy Body Dementia · 170***M. Otto***Subcortical Arteriosclerotic Encephalopathy · 173***M. Otto***Frontotemporal Lobar Degeneration · 171***M. Otto***Creutzfeldt-Jakob Disease · 174***M. Otto***Psychiatric Disorders · 176***M. Uhr***12 Cerebral Ischemia and Hemorrhage · 179***E. Stolz, P. Oschmann***Ischemic Cerebral Infarction · 179****Subarachnoid Hemorrhage · 183****Intracerebral Hemorrhage · 182****Cerebral Hypoxia · 185****13 Polyneuropathies · 187***B. Wildemann*

**14 Pseudotumor Cerebri, Ventricular Drainage, and Neurosurgery · 194***E. Stolz, P. Oschmann*

---

**Pseudotumor Cerebri · 194****Diagnosis of Cerebrospinal Rhinorrhea and Otorrhea · 195****External Ventricular Drainage, Ventriculoatrial and  
Ventriculoperitoneal Shunts · 194****15 Epileptic Seizures · 197***J. Brettschneider, H. Tumani*

---

**16 Brain Tumors · 200***B. Storch-Hagenlocher, M. Vogt-Schaden*

---

**Primary Brain Tumors · 200***B. Storch-Hagenlocher***Neoplastic Meningitis in Malignant Non-Hodgkin  
Lymphoma and Leukemia · 205***M. Vogt-Schaden***Malignant Non-Hodgkin Lymphoma · 205****Leukemia · 205****Lymphomatous Meningitis · 205****Secondary Brain Tumors · 202***M. Vogt-Schaden***17 Metabolic Diseases · 209***F. Ebinger*

---

**Mitochondrial Diseases · 211****Leukodystrophy/Leukoencephalopathy in Organic  
Aciduria · 224****Lysosomal Diseases · 216****Disorders of Copper Metabolism · 224****Peroxisomal Diseases · 222****Cerebrotendinous Xanthomatosis · 223****18 Parasitoses and Tropical Diseases · 226***H. Reiber, E. Schmutzhard*

---

**Appendix · 233****19 CSF Analysis Report · 235***H. Reiber*

---

**Integrated CSF Report · 235****Evaluation · 238****CSF Analysis Procedure · 235****Interpretation · 246**

---

**20 Quality Assessment in the CSF Laboratory · 249***H. Reiber***Quality Assessment in Laboratory Medicine · 249****Internal Quality Control for CSF proteins (Total Protein, Albumin, IgG, IgA, IgM) · 250****The INSTAND Interlaboratory CSF Survey · 251**

EQA for CSF proteins (Total Protein, Albumin, IgG, IgA, IgM) · 251

CSF Survey: Specific Antibodies in CSF and Serum · 252

**CSF Survey: Oligoclonal IgG · 252**

Manufacturer-Related Versus Patient-Related Evaluation in Interlaboratory Surveys · 252

**CSF Survey: Lactate, Glucose and Surrogate Markers · 253****CSF Cytology: Quality Control and Interpretation Training · 253**

---

**21 Reference Ranges of Analytes in CSF and Serum · 254***H. Reiber***Electrolytes and Substrates · 254****Amino Acids, Lipids, and Vitamins · 254****Proteins · 254****Cells · 255**